BeyondSpring Inc. (NASDAQ:BYSI) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus price objective of $50.00 for the company and are predicting that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also assigned BeyondSpring an industry rank of 108 out of 265 based on the ratings given to related companies.
BYSI has been the topic of several research analyst reports. Zacks Investment Research raised BeyondSpring from a “sell” rating to a “hold” rating in a research report on Tuesday. Rodman & Renshaw boosted their price objective on BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, July 14th. Finally, HC Wainwright set a $43.00 price objective on BeyondSpring and gave the stock a “buy” rating in a research report on Wednesday, May 31st.
BeyondSpring (BYSI) traded up 0.18% during midday trading on Wednesday, reaching $38.36. The company had a trading volume of 917 shares. BeyondSpring has a 12-month low of $16.55 and a 12-month high of $48.49. The stock’s 50 day moving average is $39.34 and its 200 day moving average is $30.30. The firm’s market capitalization is $832.68 million.
About BeyondSpring
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Get a free copy of the Zacks research report on BeyondSpring (BYSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
